Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke (NCT05910125) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
China472 participantsStarted 2023-07
Plain-language summary
An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.
Who can participate
Age range40 Years ā 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Aged 40-80 years.
ā. Diagnosed with acute ischemic stroke, NIHSS ā¤ 5 and single item score ā¤ 1 for vision, language, single limb, and no impairment of consciousness.
ā. Time from symptoms onset to randomization within 4.5 hours; the onset time refers to the "Last Known Normal" (LKN).